Molecular Formula | C11H15N5O3 |
Molar Mass | 265.27 |
Density | 1.630±0.06 g/cm3(Predicted) |
Boling Point | 661.2±55.0 °C(Predicted) |
pKa | 13.78±0.40(Predicted) |
Storage Condition | 2-8℃ |
In vitro study | Cellular kinases phosphorylate Galidesivir (BCX4430) to a triphosphate that mimics ATP; viral RNA polymerases incorporate the drug's monophosphate nucleotide into the growing RNA chain, causing premature chain termination. Galidesivir effectively inhibits the infection of Vero cells with YFV. The EC50 determined by the neutral red uptake assay is 8.3 μg/ml (24.5 μM). |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.77 ml | 18.849 ml | 37.698 ml |
5 mM | 0.754 ml | 3.77 ml | 7.54 ml |
10 mM | 0.377 ml | 1.885 ml | 3.77 ml |
5 mM | 0.075 ml | 0.377 ml | 0.754 ml |
biological activity | Galidesivir (BCX4430), an adenosine analog and a direct-acting anti-Virus drug, capable of disrupting Virus of RNA-dependent RNA polymerase (RdRp) activity. Galidesivir is active in vitro against a variety of RNA Virus pathogens, including filamentous Virus and emerging infectious agents such as MERS-CoV, SARS-CoV and SARS-CoV-2. The EC50 of Galidesivir for some negative-sense RNAs Virus is in the range of ~ 3 to ~ 68 μm. |
Target | RdRp |
Animal Model: | Female Syrian golden hamsters (hamsters infected with YF virus) |
Dosage: | 4 mg/kg of body weight |
Administration: | I.p.; twice daily for 7 days |
Result: | Significantly improved the survival of hamsters infected with YFV. |